204 related articles for article (PubMed ID: 21789506)
1. Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.
Karmaus PW; Chen W; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2012 Dec; 7(4):843-55. PubMed ID: 21789506
[TBL] [Abstract][Full Text] [Related]
2. Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2.
Karmaus PW; Chen W; Crawford R; Kaplan BL; Kaminski NE
Toxicol Sci; 2013 Feb; 131(2):419-33. PubMed ID: 23152191
[TBL] [Abstract][Full Text] [Related]
3. CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection.
Newton CA; Chou PJ; Perkins I; Klein TW
J Neuroimmune Pharmacol; 2009 Mar; 4(1):92-102. PubMed ID: 18792785
[TBL] [Abstract][Full Text] [Related]
4. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol.
Buchweitz JP; Karmaus PW; Williams KJ; Harkema JR; Kaminski NE
J Leukoc Biol; 2008 Mar; 83(3):785-96. PubMed ID: 18073275
[TBL] [Abstract][Full Text] [Related]
5. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.
Springs AE; Karmaus PW; Crawford RB; Kaplan BL; Kaminski NE
J Leukoc Biol; 2008 Dec; 84(6):1574-84. PubMed ID: 18791168
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the role of CB
Li X; Hempel BJ; Yang HJ; Han X; Bi GH; Gardner EL; Xi ZX
Eur Neuropsychopharmacol; 2021 Feb; 43():38-51. PubMed ID: 33334652
[TBL] [Abstract][Full Text] [Related]
7. Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.
Lu H; Kaplan BL; Ngaotepprutaram T; Kaminski NE
J Leukoc Biol; 2009 Feb; 85(2):322-9. PubMed ID: 18988696
[TBL] [Abstract][Full Text] [Related]
8. Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.
Lu T; Newton C; Perkins I; Friedman H; Klein TW
Eur J Pharmacol; 2006 Feb; 532(1-2):170-7. PubMed ID: 16443217
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells.
Rao GK; Zhang W; Kaminski NE
J Leukoc Biol; 2004 May; 75(5):884-92. PubMed ID: 14966196
[TBL] [Abstract][Full Text] [Related]
10. Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.
Chen W; Crawford RB; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2015 Jun; 10(2):344-55. PubMed ID: 25900076
[TBL] [Abstract][Full Text] [Related]
11. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
[TBL] [Abstract][Full Text] [Related]
12. Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.
Pandey R; Hegde VL; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2011 Sep; 338(3):819-28. PubMed ID: 21673072
[TBL] [Abstract][Full Text] [Related]
13. Delta 9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells.
Fischer-Stenger K; Updegrove AW; Cabral GA
Proc Soc Exp Biol Med; 1992 Jul; 200(3):422-30. PubMed ID: 1319584
[TBL] [Abstract][Full Text] [Related]
14. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
15. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
17. Similarities and differences upon binding of naturally occurring Δ
Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
19. Δ
Henriquez JE; Bach AP; Matos-Fernandez KM; Crawford RB; Kaminski NE
J Neuroimmune Pharmacol; 2020 Dec; 15(4):863-874. PubMed ID: 32215844
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]